Innate immune cells at the injection site responsive to MF59 adjuvant

Innate immune cells at the injection site responsive to MF59 adjuvant represent the primary cellular mediators of the MF59 oil-in-water emulsion's vaccine-enhancing effects. Upon injection, MF59 induces a rapid and transient local inflammatory response characterized by the secretion of chemokines such as CCL2, CCL3, and CXCL8, which recruit monocytes, macrophages, and dendritic cells to the site (O'Hagan et al., 2012). Unlike many other adjuvants, MF59 does not directly bind to specific pattern recognition receptors (PRRs) like Toll-like receptors; instead, it triggers the release of endogenous danger signals, including ATP, which act as 'alarmin' molecules to activate the innate system (Vono et al., 2013). These recruited cells efficiently take up vaccine antigens and transport them to the draining lymph nodes, where they facilitate the priming of adaptive immune responses. This cellular recruitment and activation are essential for the increased antibody titers and improved T-cell responses observed with MF59-adjuvanted vaccines, such as those used for seasonal and pandemic influenza (Seubert et al., 2008). The process creates a local 'immunocompetent environment' that bridges the gap between innate and adaptive immunity. Understanding this cellular response is critical for the design of next-generation adjuvants and vaccines targeting infectious diseases.

Other names

MF59-responsive innate immune cellsRecruited inflammatory cellsMF59-induced cellular infiltrateAntigen-presenting cells at MF59 injection site

MF59 creates a local immunocompetent environment by inducing the release of chemokines (e.g., CCL2, CXCL8) and danger-associated molecular patterns (DAMPs) like ATP, which recruit and activate monocytes, macrophages, and dendritic cells to the injection site to enhance antigen uptake and transport to lymph nodes (O'Hagan et al., 2012; Vono et al., 2013).